Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IM-201
- Development stage
- Preclinical
- Lead developer
- ImmunAbs
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravitreal
01
Overview
IM-201 is a monoclonal antibody currently in development by ImmunAbs for the treatment of diabetic retinopathy. It is designed to target a novel, non-VEGF antigen, distinguishing it from current standard-of-care anti-VEGF therapies such as ranibizumab or aflibercept. By addressing a VEGF-independent pathway, IM-201 aims to provide a new therapeutic option for patients who are refractory to or experience suboptimal results with existing treatments. The drug is intended to address the underlying pathological mechanisms of diabetic eye disease through a mechanism that does not rely on the inhibition of vascular endothelial growth factor signaling.
Beyond the preview
Go deeper on IM-201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IM-201.